Novo Nordisk Invests €432 Million to Expand Athlone Manufacturing Facility
Introduction
Novo Nordisk has announced an investment of €432 million to expand its tabletting facility in Ireland. This expansion will increase the company’s capacity to produce oral GLP-1 treatments, supporting current and future demand outside the US.
Features
Upgrade and retrofit of the existing plant to enhance production capabilities. Additional capacity for oral GLP-1 medicines.
Focus on efficient, high-quality, and environmentally sustainable manufacturing.
The facility currently employs 260 staff, with construction expected to create up to 500 jobs.
The site covers 45 acres (18 hectares), allowing significant room for future growth.
Construction is expected to be completed gradually from the end of 2027 through 2028.
Specifications
| Name | Novo Nordisk |
| Budget | €432 Million |
| Type | Expansion |
| Year of Completion | 2027-2028 |
